Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and P-GemOx in Newly Diagnosed ENKTL
NCT06824883Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Peking Union Medical College Hospital. Started May 2024; status: recruiting.
02
Drugs
sintilimab
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT06824883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06824883.